CJC-1295 DAC Guide

Understanding the Drug Affinity Complex Modification

The "DAC" in CJC-1295 DAC refers to a Drug Affinity Complex—a chemical modification that attaches the peptide to human serum albumin via a thioester bond. Albumin is the most abundant protein in blood, making up roughly 50% of total plasma protein. By binding to albumin, CJC-1295 DAC gains several critical advantages over the unmodified peptide.

In its natural form, CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of only 30 minutes. The pituitary rapidly absorbs it, triggers a GH pulse, and the peptide is cleared. This creates an acute, time-limited growth hormone response. The DAC modification changes this fundamental kinetics: instead of rapid absorption and clearance, the albumin-bound complex circulates continuously, releasing small amounts of active CJC-1295 throughout the week. This results in sustained elevation of growth hormone without the sharp peaks and troughs of pulsatile dosing.

The albumin-peptide complex is too large to cross the blood-brain barrier or bind directly to receptors—but as albumin naturally circulates and breaks down over the course of days, tiny amounts of free CJC-1295 are released, maintaining tonic GH stimulation. Think of it as a slow-release formulation that leverages the body's own protein carrier.

Half-Life and Pharmacokinetics: Why 6-8 Days Matters

The extended half-life is the defining feature of CJC-1295 DAC. Standard CJC-1295 requires injection every 6 hours or daily dosing to maintain any steady-state GH elevation. CJC-1295 DAC requires only one injection per week, making it dramatically more practical for long-term protocols.

This extended circulation time has important downstream effects. Because GH elevation is sustained rather than pulsatile, cortisol suppression is typically less marked—pulsatile GH triggers more aggressive negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis. And because albumin protects the peptide from rapid enzymatic degradation, less frequent dosing is needed to achieve target IGF-1 levels.

Studies show that peak GH levels with CJC-1295 DAC are typically 60-80% lower than pulsatile dosing, but the area-under-the-curve (AUC)—the cumulative GH exposure over time—is often higher due to the sustained release. For anabolic adaptation and lean mass gain, sustained moderate elevation is often superior to sharp spikes followed by crashes.

Mechanism of Action: GHRH Agonism and Sustained Elevation

CJC-1295 DAC works by binding to GHRH (growth hormone-releasing hormone) receptors on somatotroph cells in the anterior pituitary. GHRH is the primary physiological signal that triggers growth hormone secretion. CJC-1295 is a synthetic GHRH analog with extended activity compared to native GHRH.

The mechanism unfolds as follows:

1. Receptor Binding: Free CJC-1295 (released from the albumin complex) binds to GHRH receptors on pituitary somatotrophs.
2. cAMP Signaling: This triggers intracellular cAMP elevation and calcium influx, leading to exocytosis of GH-containing granules.
3. Sustained Tone: Because albumin continuously releases small amounts of CJC-1295, there is persistent low-level GHRH receptor activation, maintaining baseline GH secretion without requiring pulsatile spikes.
4. IGF-1 Production: Elevated circulating GH stimulates hepatic and peripheral IGF-1 production, driving anabolic effects on muscle, bone, and metabolism.

One critical point: CJC-1295 DAC does not directly suppress somatostatin (the GH inhibitory hormone). It works by continuously stimulating GHRH. Some research suggests that sustained activation of GHRH signaling may eventually trigger compensatory somatostatin elevation, which is why many protocols combine CJC-1295 DAC with ghrelin agonists like ipamorelin to maximize GH output.

CJC-1295 DAC vs. CJC-1295 Without DAC: Pulsatile vs. Sustained

Understanding the difference between these two formulations is essential for protocol design.

For most users, CJC-1295 DAC's simplicity—one injection per week, no stacking required, consistent IGF-1 elevation—makes it preferable for long-term use. CJC-1295 without DAC shines in research settings where acute GH pulses are prioritized and when combined with ghrelin agonists for synergistic effect.

Dosing Protocol: 2 mg Once Weekly

The standard research dose for CJC-1295 DAC is 2 mg injected subcutaneously once per week. Most protocols use Monday or Friday as the injection day for consistency.

Preparation and Administration:

• Reconstitution: Lyophilized CJC-1295 DAC is reconstituted with sterile bacteriostatic water at a concentration of typically 2 mg per vial. Once reconstituted, the peptide is stable refrigerated (2-8°C) for 2-3 weeks.
• Injection Site: Subcutaneous injection into the abdomen or love handles is standard. Rotate sites weekly to minimize lipohypertrophy.
• Injection Timing: No specific timing is required—since half-life is 6-8 days, one injection per week maintains steady state. Consistency (same day each week) is more important than timing of day.
• No Stacking Required: Unlike CJC-1295 without DAC, the DAC version produces meaningful GH elevation on its own. Stacking with ipamorelin is optional and typically reserved for protocols seeking maximum IGF-1 elevation.

Some advanced users employ a "2 mg every 5 days" protocol to maintain even steadier levels, but research data does not support additional benefit over once-weekly dosing. Adherence and consistency matter more than micro-dosing.

GH Bleed: Sustained Elevation and Basal GH

One critical concept is "GH bleed"—the continuous background elevation of growth hormone that CJC-1295 DAC produces. Unlike pulsatile dosing (which relies on sharp spikes followed by baseline), DAC produces constant modest elevation. This has both advantages and disadvantages.

GH bleed from CJC-1295 DAC is generally not a negative—it drives IGF-1 elevation continuously, which is the primary anabolic signal. Basal GH remains suppressed by somatostatin during non-injection periods on other protocols, but with sustained GHRH activation from DAC, basal GH stays elevated. This is favorable for anabolic purposes.

Research Data: IGF-1 Elevation and Metabolic Effects

Published research on CJC-1295 DAC is limited compared to GH itself, but available data is informative.

IGF-1 Elevation: Clinical studies on patients receiving CJC-1295 DAC for GH deficiency show consistent IGF-1 elevation of 50-150% above baseline, depending on dose and baseline GH status. In one small study, patients receiving 2 mg every 7 days achieved IGF-1 levels in the upper-normal to elevated range, maintained over 12 weeks without tachyphylaxis (tolerance development).

Body Composition: Research in GH-deficient adults treated with CJC-1295 DAC shows improvements in lean mass and reduction in abdominal fat over 6-12 months. Muscle strength and exercise capacity improve modestly. These effects are consistent with what would be expected from IGF-1 elevation.

Metabolic Safety: No tachyphylaxis or receptor desensitization was observed in 6-month studies, meaning the peptide maintains efficacy without dose escalation. Glucose handling remained stable in non-diabetic subjects; some diabetic subjects showed modest increases in glucose that normalized with standard diabetes management.

Bone Density: GH-deficient patients treated with CJC-1295 DAC showed modest improvement in bone mineral density at lumbar spine and hip over 12 months, though gains were smaller than with recombinant GH replacement.

Side Effects and Safety Considerations

General Safety: CJC-1295 DAC is well-tolerated in clinical populations. Adverse events in published trials were rare and mild, primarily injection site reactions and transient water retention.

Potential Side Effects (by frequency):

• Very Common: None (truly adverse effects are rare)
• Common: Mild water/electrolyte retention (easily managed with hydration), transient flushing or warmth, mild appetite increase
• Uncommon: Joint aches (from rapid IGF-1 elevation), mild carpal tunnel symptoms (GH-related), headache (water retention)
• Rare: Hyperglycemia (in predisposed individuals), lipoatrophy at injection sites (with poor site rotation)

Cortisol Considerations: Unlike pulsatile GH or high-dose ipamorelin, CJC-1295 DAC's sustained elevation produces modest cortisol elevation. Serum cortisol typically increases 10-30% above baseline with once-weekly dosing. This is generally not problematic for healthy individuals, but those with underlying adrenal insufficiency or chronic stress should monitor.

Insulin Resistance: High-dose GH is known to reduce insulin sensitivity. CJC-1295 DAC at standard doses rarely causes clinically significant glucose intolerance in non-diabetic individuals, but fasting glucose and insulin should be monitored annually.

Comparing CJC-1295 DAC with Other GH-Releasing Peptides

Understanding where DAC fits in the broader landscape of GH secretagogues is valuable for protocol design:

vs. Ipamorelin: Ipamorelin is a ghrelin agonist (acts on a different receptor) and produces acute GH spikes but lower total GH exposure. It's ideal for stacking with CJC-1295 without DAC for synergistic effect. Ipamorelin alone will not achieve the IGF-1 elevation that CJC-1295 DAC does.

vs. GHRP-2 and GHRP-6: These are non-selective ghrelin agonists that cause significant cortisol and prolactin elevation along with GH. CJC-1295 DAC is cleaner—it targets GHRH specifically and does not trigger the off-target hormone release.

vs. Recombinant Human GH: Exogenous GH is continuous (not pulsatile) and achieves higher IGF-1 elevation more reliably, but CJC-1295 DAC is legal to research in most jurisdictions and stimulates the body's own GH production rather than suppressing it. GH produces some anabolic effects independent of IGF-1 (direct muscle and bone effects), which peptides cannot fully replicate.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions